Insider Selling: Veeva Systems Inc. (NYSE:VEEV) EVP Sells 3,391 Shares of Stock

Veeva Systems Inc. (NYSE:VEEV - Get Free Report) EVP Alan Mateo sold 3,391 shares of the business's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $200.86, for a total value of $681,116.26. Following the completion of the sale, the executive vice president now directly owns 21,983 shares of the company's stock, valued at approximately $4,415,505.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Veeva Systems Price Performance

VEEV stock traded up $1.89 on Tuesday, reaching $200.95. 902,714 shares of the company traded hands, compared to its average volume of 981,032. Veeva Systems Inc. has a one year low of $160.21 and a one year high of $236.90. The company has a market cap of $32.42 billion, a P/E ratio of 62.41, a price-to-earnings-growth ratio of 2.00 and a beta of 0.74. The firm has a fifty day simple moving average of $220.53 and a 200-day simple moving average of $202.75.

Veeva Systems (NYSE:VEEV - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The technology company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Veeva Systems had a return on equity of 11.26% and a net margin of 22.24%. The company had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. On average, sell-side analysts forecast that Veeva Systems Inc. will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on VEEV shares. The Goldman Sachs Group boosted their target price on Veeva Systems from $219.00 to $248.00 and gave the company a "buy" rating in a research note on Friday, March 1st. JPMorgan Chase & Co. boosted their target price on Veeva Systems from $183.00 to $222.00 and gave the company a "neutral" rating in a research note on Wednesday, March 13th. Stifel Nicolaus upped their price target on Veeva Systems from $205.00 to $250.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Citigroup upped their price target on Veeva Systems from $240.00 to $264.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $250.00 price target on shares of Veeva Systems in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $234.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OFI Invest Asset Management bought a new stake in shares of Veeva Systems in the 3rd quarter worth $25,000. Operose Advisors LLC bought a new stake in shares of Veeva Systems in the 3rd quarter worth $29,000. DSM Capital Partners LLC bought a new stake in shares of Veeva Systems in the 4th quarter worth $29,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Veeva Systems in the 4th quarter worth $32,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Veeva Systems by 81.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 171 shares of the technology company's stock worth $35,000 after purchasing an additional 77 shares in the last quarter. Institutional investors own 88.20% of the company's stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.